Page last updated: 2024-11-12

me1036

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ME1036: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10300326
CHEMBL ID387640
SCHEMBL ID304850
MeSH IDM0473038

Synonyms (15)

Synonym
CHEMBL387640 ,
me1036
SCHEMBL304850
432038-96-5
33501r83o2 ,
cp-5609
unii-33501r83o2
me-1036
pyridinium, 1-(2-amino-2-oxoethyl)-3-((2-((4s,5r,6s)-2-carboxy-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-en-3-yl)imidazo(5,1-b)thiazol-7-yl)carbonyl)-, inner salt
bdbm50483328
LZKPUSJSJVEXAW-WDXSGGTDSA-N ,
(1s,5r,6s)-2-[7-(1-carbamoylmethylpyridinium-3-yl)carbonylimidazo[5,1-b]thiazol-2-yl]-6-[(1r)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate
Q27256228
(4s,5r,6s)-3-[7-[1-(2-amino-2-oxoethyl)pyridin-1-ium-3-carbonyl]imidazo[5,1-b][1,3]thiazol-2-yl]-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
AKOS040751289

Research Excerpts

Effects

ExcerptReferenceRelevance
"ME1036 has been shown to be strongly active against genotypic penicillin-intermediate S."( Correlation of the antimicrobial activity of ME1036 with its binding affinities to the penicillin-binding proteins from Streptococcus pneumoniae strains.
Hirai, Y; Ida, T; Maebashi, K; Takahata, S; Yamada, K, 2011
)
1.35

Dosage Studied

ExcerptRelevanceReference
" Compared with vancomycin, ME1036 reduced the bacterial counts in the vegetations at a lower dosage or over a shorter period of administration when it was used for the treatment of MRSA endocarditis."( Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
Hirai, Y; Kijima, K; Kurazono, M; Nagura, J; Shitara, E; Sugano, T; Takahata, S; Takayama, Y; Tanaka, Y; Yamada, K; Yonezawa, M, 2005
)
0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID284141Antibacterial activity against Staphylococcus aureus 209P JC1 by agar dilution method2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems.
AID284147Antibacterial activity against Moraxella catarrhalis W-0500 by agar dilution method2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems.
AID519138Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID284146Antibacterial activity against Klebsiella pneumoniae GN69 by agar dilution method2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems.
AID284143Antibacterial activity against carbapenem and methicillin-resistant Staphylococcus aureus M126HR by agar dilution method2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems.
AID284144Antibacterial activity against penicillin-resistant Streptococcus pneumoniae KK133 by agar dilution method2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems.
AID284145Antibacterial activity against Escherichia coli NIHJ JC2 by agar dilution method2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems.
AID284142Antibacterial activity against methicillin-resistant Staphylococcus aureus M126 by agar dilution method2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems.
AID284148Antibacterial activity against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae 870 by agar dilution method2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and SAR study of novel 7-(pyridinium-3-yl)-carbonyl imidazo[5,1-b]thiazol-2-yl carbapenems.
AID560209Binding affinity to methicillin-resistant Staphylococcus aureus MF535HR PBP 2a by competitive binding assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (90.91)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.95 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]